Literature DB >> 11259090

Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes.

Y Matsumoto1, K Tanaka, F Nakatani, T Matsunobu, S Matsuda, Y Iwamoto.   

Abstract

Chromosomal translocation t(11;22)(q24:q12) is detected in approximately 90% of tumours of the Ewing family (ET). This translocation results in EWS-Fli1 gene fusion which produces a EWS-Fli1 fusion protein acting as an aberrant transcriptional activator. We previously reported that the inhibition of EWS-Fli1 expression caused the G(0)/G(1)arrest of ET cells. We, therefore, hypothesized that EWS-Fli1 may affect the expression of G(1)regulatory genes. Downregulation of EWS-Fli1 fusion proteins was observed 48 hours after the treatment with EWS-Fli1 antisense oligonucleotides. The expressions of G(1)cyclins, cyclin D1 and cyclin E, were markedly decreased in parallel with the reduction of EWS-Fli1 fusion protein. On the other hand, the expression of p21 and p27, which are important cyclin-dependent kinase inhibitors (CKIs) for G(1)--S transition, was dramatically increased after the treatment with EWS-Fli1 antisense oligonucleotides. RT-PCR analysis showed that alteration of the expressions of the cyclins and CKIs occurred at the mRNA level. Furthermore, transfection of EWS-Fli1 cDNA to NIH3T3 caused transformation of the cells and induction of the expression of cyclin D1 and E. Clinical samples of ET also showed a high level of expression of cyclin D1 mRNA, whereas mRNAs for p21 and p27 were not detected in the samples. These findings strongly suggest that the G(1)--S regulatory genes may be involved in downstream of EWS-Fli1 transcription factor, and that the unbalanced expression of G(1)--S regulatory factors caused by EWS-Fli1 may lead to the tumorigenesis of ET. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259090      PMCID: PMC2363806          DOI: 10.1054/bjoc.2000.1652

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter.

Authors:  J Botz; K Zerfass-Thome; D Spitkovsky; H Delius; B Vogt; M Eilers; A Hatzigeorgiou; P Jansen-Dürr
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

2.  Block of T lymphocyte differentiation by activation of the cAMP-dependent signal transduction pathway.

Authors:  E Lalli; P Sassone-Corsi; R Ceredig
Journal:  EMBO J       Date:  1996-02-01       Impact factor: 11.598

3.  EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.

Authors:  M Giovannini; J A Biegel; M Serra; J Y Wang; Y H Wei; L Nycum; B S Emanuel; G A Evans
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

4.  Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.

Authors:  C Albanese; J Johnson; G Watanabe; N Eklund; D Vu; A Arnold; R G Pestell
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

5.  The establishment and characterization of a peripheral neuroepithelioma cell line in soft tissue of extremity.

Authors:  K Tanaka; Y Iwamoto; Y Noguchi; Y Oda; Y Sugioka
Journal:  Lab Invest       Date:  1995-02       Impact factor: 5.662

6.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.

Authors:  M Liu; M H Lee; M Cohen; M Bommakanti; L P Freedman
Journal:  Genes Dev       Date:  1996-01-15       Impact factor: 11.361

7.  Deregulation of cyclin E in breast cancer.

Authors:  K Keyomarsi; D Conte; W Toyofuku; M P Fox
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

8.  Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.

Authors:  M Ouchida; T Ohno; Y Fujimura; V N Rao; E S Reddy
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

9.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

10.  Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.

Authors:  Y E Chin; M Kitagawa; W C Su; Z H You; Y Iwamoto; X Y Fu
Journal:  Science       Date:  1996-05-03       Impact factor: 47.728

View more
  25 in total

1.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

Review 2.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 3.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

4.  Anti-Epileptic Drug Targets Ewing Sarcoma.

Authors:  Shubhalaxmi Kayarthodi; Yasuo Fujimura; Jinbo Fang; Sharif Morsalin; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-06-01

5.  Neural differentiation arrest in embryonal carcinoma cells with forced expression of EWS-FLI1.

Authors:  Yu Yang; Lanjing Zhang; Yanyu Wei; Hua Wang; Mariko Fukuma; Hao Xu; Wei Xiong; Jie Zheng
Journal:  J Neurooncol       Date:  2008-07-12       Impact factor: 4.130

6.  Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.

Authors:  Michele Dowless; Caitlin D Lowery; Terry Shackleford; Matthew Renschler; Jennifer Stephens; Robert Flack; Wayne Blosser; Simone Gupta; Julie Stewart; Yue Webster; Jack Dempsey; Alle B VanWye; Philip Ebert; Philip Iversen; Jonathan B Olsen; Xueqian Gong; Sean Buchanan; Peter Houghton; Louis Stancato
Journal:  Clin Cancer Res       Date:  2018-08-21       Impact factor: 12.531

7.  Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.

Authors:  Hayriye V Erkizan; Lauren J Scher; S Ellen Gamble; Julie S Barber-Rotenberg; Kamal P Sajwan; Aykut Üren; Jeffrey A Toretsky
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

8.  Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells.

Authors:  Benjamin Joachim Schmiedel; Christoph Hutter; Manuela Hesse; Martin Sebastian Staege
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

9.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

10.  Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer.

Authors:  Gabriel Sanchez; Danielle Bittencourt; Karine Laud; Jérôme Barbier; Olivier Delattre; Didier Auboeuf; Martin Dutertre
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.